The Forces Behind Cell Movement

由 Ananthakrishnan, Revathi, Ehrlicher, Allen
出版 2007

Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials

由 Ananthakrishnan, Revathi, Green, Stephanie, Li, Daniel, LaValley, Michael
發表在 Contemp Clin Trials Commun (2018)

2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy

由 Ananthakrishnan, Revathi, Green, Stephanie, Li, Daniel, LaValley, Michael
發表在 Contemp Clin Trials Commun (2019)

Weak Force Stalls Protrusion at the Leading Edge of the Lamellipodium

由 Bohnet, Sophie, Ananthakrishnan, Revathi, Mogilner, Alex, Meister, Jean-Jacques, Verkhovsky, Alexander B.
出版 2006

Systematic comparison of the statistical operating characteristics of various Phase I oncology designs

由 Ananthakrishnan, Revathi, Green, Stephanie, Chang, Mark, Doros, Gheorghe, Massaro, Joseph, LaValley, Michael
發表在 Contemp Clin Trials Commun (2016)

A mitotic kinesin-6, Pav-KLP, mediates interdependent cortical reorganization and spindle dynamics in Drosophila embryos

由 Sommi, Patrizia, Ananthakrishnan, Revathi, Cheerambathur, Dhanya K., Kwon, Mijung, Morales-Mulia, Sandra, Brust-Mascher, Ingrid, Mogilner, Alex
出版 2010

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma()

由 Geoerger, Birgit, Kieran, Mark W., Grupp, Stephan, Perek, Danuta, Clancy, Jill, Krygowski, Mizue, Ananthakrishnan, Revathi, Boni, Joseph P., Berkenblit, Anna, Spunt, Sheri L.
出版 2011

Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma

由 Sangha, Randeep, Davies, Andrew, Dang, Nam H., Ogura, Michinori, MacDonald, David A., Ananthakrishnan, Revathi, Paccagnella, M. Luisa, Vandendries, Erik, Boni, Joseph, Goh, Yeow Tee
發表在 J Drug Assess (2017)

Optical Deformability as an Inherent Cell Marker for Testing Malignant Transformation and Metastatic Competence

由 Guck, Jochen, Schinkinger, Stefan, Lincoln, Bryan, Wottawah, Falk, Ebert, Susanne, Romeyke, Maren, Lenz, Dominik, Erickson, Harold M., Ananthakrishnan, Revathi, Mitchell, Daniel, Käs, Josef, Ulvick, Sydney, Bilby, Curt
出版 2005

Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors

由 Spunt, Sheri L., Grupp, Stephan A., Vik, Terry A., Santana, Victor M., Greenblatt, David J., Clancy, Jill, Berkenblit, Anna, Krygowski, Mizue, Ananthakrishnan, Revathi, Boni, Joseph P., Gilbertson, Richard J.
出版 2011

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study

由 DeAngelo, Daniel J., Stock, Wendy, Stein, Anthony S., Shustov, Andrei, Liedtke, Michaela, Schiffer, Charles A., Vandendries, Erik, Liau, Katherine, Ananthakrishnan, Revathi, Boni, Joseph, Laird, A. Douglas, Fostvedt, Luke, Kantarjian, Hagop M., Advani, Anjali S.
發表在 Blood Adv (2017)